A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Trial Profile

A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs RG 4733 (Primary) ; Dexamethasone
  • Indications CNS cancer; Haematological malignancies; Leukaemia; Lymphoma; Solid tumours; T-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top